Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 6:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 408 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Glaucoma and Ocular Hypertension Clear all
Completed Phase 1Phase 2 Interventional

A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01123785
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
INO-8875, Placebo
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 77 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 10, 2026, 6:58 PM EDT
Active, not recruiting No phase listed Observational

Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes

NCT05506423
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
CycloPen Cyclodialysis System
Device
Lead sponsor
Iantrek, Inc.
Industry
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
15
States / cities
Newport Beach, California • Cape Coral, Florida • DeLand, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 2 Interventional Results available

Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution

NCT02874846
View directory record Official record
Conditions
Ocular Hypertension, Open Angle Glaucoma
Interventions
Netarsudil ophthalmic solution 0.02%, Netarsudil Ophthalmic Solution Vehicle
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 10, 2026, 6:58 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study

NCT05695027
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Dietary supplements - Nicotinamide and Pyruvate, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
3
States / cities
Palo Alto, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 4 Interventional Results available

A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension

NCT01525173
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
0.1% brimonidine tartrate ophthalmic solution, 0.01% bimatoprost ophthalmic solution, 0.2% hypromellose lubricant eye drops, latanoprost 0.005% ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Deerfield Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 10, 2026, 6:58 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

NCT04499248
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AGN-193408 SR, Lumigan, Sham Administration, Lumigan Vehicle
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
42
States / cities
Sun City, Arizona • Glendale, California • Inglewood, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT02059278
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
T-2345, Xalatan
Drug
Lead sponsor
Nephron Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 1Phase 2 Interventional

Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension

NCT00846989
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
RKI983A, Latanoprost
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
29
States / cities
Artesia, California • Inglewood, California • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 10, 2026, 6:58 PM EDT
Withdrawn Not applicable Interventional

IOP and Medication Reduction in MIGS Procedures

NCT04202510
View directory record Official record
Conditions
Open Angle Glaucoma, Primary Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma in Both Eyes
Interventions
Glaucoma and Cataract Surgery
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma

NCT02855450
View directory record Official record
Conditions
Glaucoma
Interventions
rhNGF, Vehicle
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Not applicable Interventional

Visual Outcomes With a Trifocal IOL in Subjects With Open-angle Glaucoma

NCT04619654
View directory record Official record
Conditions
Cataract, IOL, Glaucoma, Open-Angle
Interventions
Cataract surgery with implantation of trifocal IOL combined with trabecular scaffold
Procedure
Lead sponsor
Vold Vision P.L.L.C
Other
Eligibility
45 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

NCT00868894
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
DE-104 medium concentration, DE-104 high concentration, Placebo, 0.005% latanoprost
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Artesia, California • Pasadena, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2011 · Synced Oct 10, 2026, 6:58 PM EDT
Completed No phase listed Observational Results available

Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (XEN LT)

NCT03868254
View directory record Official record
Conditions
Glaucoma
Interventions
XEN Group, Phacoemulsification
Device · Procedure
Lead sponsor
Allergan
Industry
Eligibility
Not listed
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 10, 2026, 6:58 PM EDT
Withdrawn Not applicable Interventional

The Changes Within the Cells of the Drainage System of the Eye in Patients With Glaucoma

NCT02524431
View directory record Official record
Conditions
Glaucoma
Interventions
Collection of trabecular meshwork tissue during surgery
Other
Lead sponsor
Wills Eye
Other
Eligibility
21 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparative Study of the Cornea/Anterior Segment OCT CASIA2 and the RTVue XR OCT Avanti With AngioVue Software

NCT04486976
View directory record Official record
Conditions
Glaucoma, Cataract
Interventions
Cornea/Anterior Segment OCT CASIA2, Optovue RTVue XR Avanti
Device
Lead sponsor
Tomey Corporation
Industry
Eligibility
22 Years and older
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 10, 2026, 6:58 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 10, 2026, 6:58 PM EDT
Recruiting Phase 3 Interventional

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

NCT07495852
View directory record Official record
Conditions
Glaucoma
Interventions
Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, placebo eye drops
Drug · Procedure · Other
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dothan, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 10, 2026, 6:58 PM EDT
Recruiting No phase listed Observational

To Study Ocular Outflow Dynamics of the Eye Using Intraoperative Tonographic Biometry and Assess Its Predictive Value in Improving Postoperative Outcomes.

NCT07425496
View directory record Official record
Conditions
Cataract, Glaucoma
Interventions
disposable Deltran I pressure sensor
Diagnostic Test
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 1 Interventional

Study of ANX007 in Participants With Primary Open-angle Glaucoma

NCT04188015
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
2.5mg ANX007, 5.0mg ANX007, Sham Procedure
Biological · Other
Lead sponsor
Annexon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Newport Beach, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 10, 2026, 6:58 PM EDT
Completed No phase listed Observational

Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy

NCT00452283
View directory record Official record
Conditions
Glaucoma, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension

NCT00947661
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
SPARC0912, Reference0912
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

NCT05335122
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
OTX-TIC low dose Travoprost Intracameral Implant, OTX-TIC high dose Travoprost Intracameral Implant, Durysta, Bimatoprost Intracameral Implant 10 µg
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
30
States / cities
Dothan, Alabama • Huntington Beach, California • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 10, 2026, 6:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prospective Retinal and Optic Nerve Vitrectomy Evaluation (PROVE) Study

NCT01162356
View directory record Official record
Conditions
Glaucoma, Macular Pucker, Macula Hole, Vitreomacular Traction, Vitreous Opacities or Hemorrhage
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 4 Interventional Results available

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

NCT00705757
View directory record Official record
Conditions
Glaucoma, Application Site Pigmentation Changes
Interventions
latanoprost, bimatoprost, travoprost
Drug
Lead sponsor
Summa Health System
Other
Eligibility
30 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Arlington Heights, Illinois • Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 10, 2026, 6:58 PM EDT